Loading publications…
The last 5 uploaded publications
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Arndt Vogel, Andrés Cervantes, Ian Chau, Bruno Daniele, Josep M. Llovet, Tim Meyer, Jean‐Charles Nault, Ulf P. Neumann, Jens Ricke, Bruno Sangro, Peter Schirmacher, Chris Verslype, Francis Zech, Dirk Arnold, Erika Martinelli (2018). Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29, pp. iv238-iv255, DOI: 10.1093/annonc/mdy308.
Article145 days agoUpdated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
Arndt Vogel, Erika Martinelli, Arndt Vogel, Andrés Cervantes, Ian Chau, Bruno Daniele, Josep M. Llovet, Tim Meyer, Jean‐Charles Nault, Ulf P. Neumann, Jens Ricke, Bruno Sangro, Peter Schirmacher, Chris Verslype, Francis Zech, Dirk Arnold, Erika Martinelli (2021). Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Annals of Oncology, 32(6), pp. 801-805, DOI: 10.1016/j.annonc.2021.02.014.
Article145 days agoCorrection to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Arndt Vogel, Andrés Cervantes, Ian Chau, Bruno Daniele, Josep M. Llovet, Tim Meyer, Jean‐Charles Nault, U. Neumann, Jens Ricke, Bruno Sangro, Peter Schirmacher, Chris Verslype, Francis Zech, Dirk Arnold, Erika Martinelli (2019). Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of Oncology, 30(5), pp. 871-873, DOI: 10.1093/annonc/mdy510.
Article145 days agoRamucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
Andrew X. Zhu, Ryan David Nipp, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Jean-Frédéric Blanc, Takuji Okusaka, Ian Chau, David Cella, Allicia C. Girvan, Jonathon Gable, Lee Bowman, Chunxiao Wang, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo (2020). Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open, 5(4), pp. e000797-e000797, DOI: 10.1136/esmoopen-2020-000797.
Article145 days agoRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Andrew X. Zhu, RS Finn, Peter R. Galle, Josep M. Llovet, Jan Blanc, Takuji Okusaka, Ian Chau, Paolo Abada, Yanzhi Hsu, Masatoshi Kudo (2018). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). Annals of Oncology, 29, pp. v122-v122, DOI: 10.1093/annonc/mdy208.
Article145 days ago